<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01461616</url>
  </required_header>
  <id_info>
    <org_study_id>NPH-Detemir-Glargine-2011</org_study_id>
    <nct_id>NCT01461616</nct_id>
  </id_info>
  <brief_title>Effect of NPH Insulin, Insulin Detemir and Insulin Glargine on GH-IGF-IGFBP Axis</brief_title>
  <official_title>Effect of NPH Insulin, Insulin Detemir and Insulin Glargine on IGFBP-1 Production and Serum IGF-I in Subjects With Type 1 Diabetes Mellitus: An Open-label, Randomised, Triple Cross-over Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective is to describe the interaction of equal doses of NPH insulin (Neutral Protamine
      Hagedorn), insulin Detemir and insulin glargine on IGFBP-1 (Insulin-like Growth Factor
      Binding Protein-1) production as well as immunoreactive and bioactive IGF-I (Insulin-like
      Growth Factor-I) after once-daily injection on three separate visits in type 1 diabetic
      subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Because of the importance of receptors activation and potential effects on the IGF system, a
      head-to-head comparison of the eventual differential impact of intermediate-acting human
      insulin (NPH), insulin detemir and insulin glargine on the growth hormone—insulin-like growth
      factor—insulin-like growth factor binding protein (GH-IGF-IGFBP) axis is relevant to be
      conducted for the safety assurance of insulin analogues. Therefore, this study aims to
      investigate whether the serum insulin profile obtained by once-daily injection of long-acting
      insulin analog, insulin detemir or insulin glargine, has a different impact on IGFBPs
      production and IGF-I concentrations (total IGF-I) bioactivity and tissue-availability as
      compared to that seen during treatment with intermediate-acting human insulin, NPH insulin.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>IGF-I(ng/ml)</measure>
    <time_frame>16 hours (from 18:00 to 10:00 next day)</time_frame>
    <description>Hourly samples will be taken from 18:00 to 10:00 next day.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IGFBP-1(ng/ml)</measure>
    <time_frame>16 hours (from 18:00 to 10:00 next day)</time_frame>
    <description>Hourly samples will be taken from 18:00 to 10:00 next day.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IGFBP-2(ng/ml)</measure>
    <time_frame>16 hours (from 18:00 to 10:00 next day)</time_frame>
    <description>Hourly samples will be taken from 18:00 to 10:00 next day.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IGFBP-3(ng/ml)</measure>
    <time_frame>16 hours (from 18:00 to 10:00 next day)</time_frame>
    <description>Hourly samples will be taken from 18:00 to 10:00 next day.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Growth Hormone(ng/ml)</measure>
    <time_frame>16 hours (from 18:00 to 10:00 next day)</time_frame>
    <description>Hourly samples will be taken from 18:00 to 10:00 next day.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>plasma glucose concentration (mmol/L) after a single injection of either NPH insulin, insulin Detemir or insulin glargine</measure>
    <time_frame>16 hours (from 18:00 to 10:00 next day)</time_frame>
    <description>Hourly samples will be taken from 18:00 to 10:00 next day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>insulin concentration (mmol/L) after a single injection of either NPH insulin, insulin Detemir or insulin glargine</measure>
    <time_frame>16 hours (from 18:00 to 10:00 next day)</time_frame>
    <description>Hourly samples will be taken from 18:00 to 10:00 next day.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>NPH insulin injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NPH insulin will be injected in random order in one of three seperated visit days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>detemir insulin injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>insulin detemir will be injected in random order in one of three seperated visit days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>glargine insulin injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>insulin glargine will be injected in random order in one of three seperated visit days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NPH</intervention_name>
    <description>equal doses of NPH insulin, insulin Detemir and insulin glargine injection</description>
    <arm_group_label>NPH insulin injection</arm_group_label>
    <other_name>NPH insulin: Insulatard</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Detemir</intervention_name>
    <description>equal doses of NPH insulin, insulin Detemir and insulin glargine injection</description>
    <arm_group_label>detemir insulin injection</arm_group_label>
    <other_name>insulin Detemir: Levemir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glargine</intervention_name>
    <description>equal doses of NPH insulin, insulin Detemir and insulin glargine injection</description>
    <arm_group_label>glargine insulin injection</arm_group_label>
    <other_name>insulin glargine: Lamtus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Informed consent obtained before any trial-related activities.

          2. Diagnosis of diabetes mellitus according to WHO criteria; history and clinical course
             consistent with type 1 diabetes mellitus.

          3. Diagnosed with diabetes for more than 6 years and using continuous subcutaneous
             insulin infusion (CSII) at least 6 months at time of inclusion.

          4. Total daily insulin dose between 0.4 and 1.4 units/kg (both values included)

          5. HbA1c between 6% and 9% (both values included).

          6. Age ≥ 18 years.

          7. BMI between 18.5 and 28 kg /m2 (including both values).

        Exclusion Criteria:

          1. Known or suspected allergy to trial product(s) or related products.

          2. Recurrent major hypoglycaemic episodes.

          3. Heart: Unstable Angina Pectoris, AMI &lt; 12 months or heart insufficiency classified
             according to NYHA III-IV

          4. Blood Pressure: Severe uncontrolled hypertension with BP &gt; 180/110 mmHg, sitting

          5. Liver: Impaired hepatic function corresponding to serum-ALAT or basic phosphatase &gt; 2
             x upper reference limit of the local laboratory.

          6. Kidneys: Impaired renal function corresponding to serum-creatinin &gt; 150 μmol/l
             according to the local laboratory.

          7. Any disease judged by the investigator to affect the trial.

          8. Pregnancy, breast-feeding or the intention of becoming pregnant or fertile women not
             using adequate contraceptive measures - adequate contraceptive method is
             sterilisation, hysterectomy or current use of contraceptive pills or intra uterine
             device.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jens Sandahl Christiansen, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Endocrinology and Internal Medicine, Aarhus University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Endocrinology and Internal Medicine, Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <reference>
    <citation>Thrailkill KM. Insulin-like growth factor-I in diabetes mellitus: its physiology, metabolic effects, and potential clinical utility. Diabetes Technol Ther. 2000 Spring;2(1):69-80. Review.</citation>
    <PMID>11467325</PMID>
  </reference>
  <reference>
    <citation>Bereket A, Lang CH, Wilson TA. Alterations in the growth hormone-insulin-like growth factor axis in insulin dependent diabetes mellitus. Horm Metab Res. 1999 Feb-Mar;31(2-3):172-81. Review.</citation>
    <PMID>10226799</PMID>
  </reference>
  <reference>
    <citation>Clemmons DR. Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer. Nat Rev Drug Discov. 2007 Oct;6(10):821-33. Review.</citation>
    <PMID>17906644</PMID>
  </reference>
  <reference>
    <citation>LeRoith D, Yakar S. Mechanisms of disease: metabolic effects of growth hormone and insulin-like growth factor 1. Nat Clin Pract Endocrinol Metab. 2007 Mar;3(3):302-10. Review.</citation>
    <PMID>17315038</PMID>
  </reference>
  <reference>
    <citation>Brismar K, Fernqvist-Forbes E, Wahren J, Hall K. Effect of insulin on the hepatic production of insulin-like growth factor-binding protein-1 (IGFBP-1), IGFBP-3, and IGF-I in insulin-dependent diabetes. J Clin Endocrinol Metab. 1994 Sep;79(3):872-8.</citation>
    <PMID>7521354</PMID>
  </reference>
  <reference>
    <citation>Janssen JA, Jacobs ML, Derkx FH, Weber RF, van der Lely AJ, Lamberts SW. Free and total insulin-like growth factor I (IGF-I), IGF-binding protein-1 (IGFBP-1), and IGFBP-3 and their relationships to the presence of diabetic retinopathy and glomerular hyperfiltration in insulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1997 Sep;82(9):2809-15.</citation>
    <PMID>9284701</PMID>
  </reference>
  <reference>
    <citation>Hanaire-Broutin H, Sallerin-Caute B, Poncet MF, Tauber M, Bastide R, Rosenfeld R, Tauber JP. Insulin therapy and GH-IGF-I axis disorders in diabetes: impact of glycaemic control and hepatic insulinization. Diabetes Metab. 1996 Jul;22(4):245-50. Review.</citation>
    <PMID>8767170</PMID>
  </reference>
  <reference>
    <citation>Ekman B, Nyström F, Arnqvist HJ. Circulating IGF-I concentrations are low and not correlated to glycaemic control in adults with type 1 diabetes. Eur J Endocrinol. 2000 Oct;143(4):505-10.</citation>
    <PMID>11022197</PMID>
  </reference>
  <reference>
    <citation>Bolli GB, Owens DR. Insulin glargine. Lancet. 2000 Aug 5;356(9228):443-5.</citation>
    <PMID>10981882</PMID>
  </reference>
  <reference>
    <citation>Hirsch IB. Insulin analogues. N Engl J Med. 2005 Jan 13;352(2):174-83. Review.</citation>
    <PMID>15647580</PMID>
  </reference>
  <reference>
    <citation>Heinemann L, Sinha K, Weyer C, Loftager M, Hirschberger S, Heise T. Time-action profile of the soluble, fatty acid acylated, long-acting insulin analogue NN304. Diabet Med. 1999 Apr;16(4):332-8.</citation>
    <PMID>10220208</PMID>
  </reference>
  <reference>
    <citation>Kurtzhals P, Schäffer L, Sørensen A, Kristensen C, Jonassen I, Schmid C, Trüb T. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes. 2000 Jun;49(6):999-1005.</citation>
    <PMID>10866053</PMID>
  </reference>
  <reference>
    <citation>Varewijck AJ, Goudzwaard JA, Brugts MP, Lamberts SW, Hofland LJ, Janssen JA. Insulin glargine is more potent in activating the human IGF-I receptor than human insulin and insulin detemir. Growth Horm IGF Res. 2010 Dec;20(6):427-31. doi: 10.1016/j.ghir.2010.10.002. Epub 2010 Nov 4.</citation>
    <PMID>21055982</PMID>
  </reference>
  <reference>
    <citation>Vigneri R, Squatrito S, Sciacca L. Insulin and its analogs: actions via insulin and IGF receptors. Acta Diabetol. 2010 Dec;47(4):271-8. doi: 10.1007/s00592-010-0215-3. Epub 2010 Aug 21. Review.</citation>
    <PMID>20730455</PMID>
  </reference>
  <reference>
    <citation>Porcellati F, Rossetti P, Candeloro P, Lucidi P, Cioli P, Andreoli AM, Ghigo E, Bolli GB, Fanelli CG. Short-term effects of the long-acting insulin analog detemir and human insulin on plasma levels of insulin-like growth factor-I and its binding proteins in humans. J Clin Endocrinol Metab. 2009 Aug;94(8):3017-24. doi: 10.1210/jc.2008-2838. Epub 2009 May 26.</citation>
    <PMID>19470629</PMID>
  </reference>
  <reference>
    <citation>Slawik M, Schories M, Busse Grawitz A, Reincke M, Petersen KG. Treatment with insulin glargine does not suppress serum IGF-1. Diabet Med. 2006 Jul;23(7):814-7.</citation>
    <PMID>16842489</PMID>
  </reference>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 24, 2011</study_first_submitted>
  <study_first_submitted_qc>October 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2011</study_first_posted>
  <last_update_submitted>December 3, 2012</last_update_submitted>
  <last_update_submitted_qc>December 3, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 4, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes Mellitus, Type 1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Isophane insulin, beef</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
    <mesh_term>Insulin Detemir</mesh_term>
    <mesh_term>Insulin, Isophane</mesh_term>
    <mesh_term>Isophane Insulin, Human</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

